ClinicalTrials.gg
CompletedNCT01986855Updated Sep 10, 2018Results posted

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

A Phase 3 interventional study of Ertugliflozin 5 mg and Placebo 5 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2018-09-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
7th of 28
468 · median 83
Started
2013
with 5 others
Phase 3
11 of 28
none open now
Registered
9th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in participants with Type 2 diabetes mellitus with Stage 3 Chronic Kidney Disease (CKD) who have inadequate glycemic control on background antihyperglycemic therapy. The duration of this trial will be up to 67 weeks. This study will consist of a 1-week Screening Period, a 10-week wash-off period from metformin, if needed, and a 2-week placebo run-in period, a 52-week double-blind treatment period, and a 14-day post-treatment follow-up period. The primary objective of this trial is to assess the hemoglobin A1C (A1C)-lowering efficacy of the addition of ertugliflozin compared to the addition of placebo with an underlying hypothesis that addition of treatment with ertugliflozin provides greater reduction in A1C compared to the addition of placebo; the primary objective will be tested for both 5-mg and 15-mg doses of ertugliflozin.

Read the detailed description

Participants who meet protocol-defined glycemic rescue criteria will be permitted to have an adjustment in the dose(s) of background antihyperglycemic agent (AHA) therapy or addition of new AHA therapy as directed by their investigator until the participant no longer meets the rescue criteria.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Type 2 diabetes mellitus in accordance with American Diabetes Association guidelines
  • Have Stage 3 chronic kidney disease
  • On stable diabetes therapy (diet/exercise therapy alone or anti-hyperglycemic agents [AHA] monotherapy or combination therapy) for at least 6 weeks prior to study participation OR on metformin (with or without diet/exercise therapy or other AHA therapy) and is willing to undergo a 10-week metformin wash-off period
  • Have an estimated (eGFR) of ≥30 to \<60 mL/min/1.73m\^2
  • (BMI) greater than or equal to 18.0 kg/m\^2
  • Male, female or surgically sterile female
  • If a female of , agrees to remain abstinent or to use (or have their partner use) 2 acceptable combinations of while participating in the trial and for 14 days after the last use of study drug.

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus or a history of ketoacidosis
  • History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrine disorders, drug - or chemical-induced, and post-organ transplant)
  • History of nephrotic range proteinuria with hypoalbuminemia and edema
  • History of rapidly progressive glomerulonephritis, lupus nephritis, renal or systemic vasculitis, renal artery stenosis with renovascular hypertension, or ischemic nephropathy
  • History of familial renal glucosuria
  • History of renal dialysis or renal transplant or renal disease requiring treatment with any agent
  • A known or intolerance to any (sodium-glucose co-transporter 2) SGLT2 inhibitor
  • On a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable
  • Has undergone bariatric surgery within the past 12 months
  • Has been treated with rosiglitazone or other SGLT2 inhibitors within 12 weeks of study participation
  • Has active, obstructive uropathy or indwelling urinary catheter
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, , or (NYHA) functional class III-IV heart failure within 3 months of study participation
  • A history of ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer
  • Known history of (HIV)
  • Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells or any other hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active or C, primary biliary cirrhosis, or active symptomatic gallbladder disease
  • Has any clinically significant malabsorption condition
  • If taking thyroid replacement therapy, has not been on a stable dose for at least 6 weeks prior to study participation
  • Has been previously randomized in a study with ertugliflozin
  • Has participated in other studies involving an drug within 30 days prior or during study participation
  • Has undergone a surgical procedure within 6 weeks prior to or during study participation
  • Has a positive urine pregnancy test
  • Is pregnant or breast-feeding, or is planning to conceive during the trial, including 14 days following the last dose of study medication
  • Planning to undergo hormonal therapy in preparation to donate eggs during the trial, including 14 days following the last dose of study medication
  • Excessive consumption of alcoholic beverages or binge drinking
  • Has donated blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
468 participants (actual)

Study arms

  • Experimental
    Ertugliflozin (5 mg)

    Ertugliflozin, 5 mg, oral, one 5 mg ertugliflozin tablet and one placebo tablet, once daily for 52 weeks

    Drug: Ertugliflozin 5 mg · Drug: Placebo 10 mg

  • Experimental
    Ertugliflozin (15 mg)

    Ertugliflozin, 15 mg, oral, one 5 mg and one 10 mg tablet, once daily for 52 weeks

    Drug: Ertugliflozin 10 mg

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo 5 mg · Drug: Placebo 10 mg

Interventions

  • Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks

    Also known as: MK-8835, PF-04971729

  • DrugPlacebo 5 mg

    Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks

  • Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks

    Also known as: MK-8835, PF-04971729

  • DrugPlacebo 10 mg

    Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in A1C at Week 26 - Excluding Rescue Approach

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 26

  2. Percentage of Participants Who Experienced an Adverse Event (AE)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 54 weeks

  3. Percentage of Participants Who Discontinued Study Treatment Due to an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Change From Baseline in A1C at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 26

  2. Change From Baseline in Body Weight at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

    This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 26

  3. Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

    This change from baseline reflects the Week 26 sitting systolic blood pressure minus the Week 0 sitting systolic blood pressure. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 26

  4. Change From Baseline in FPG at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

    This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 26

  5. Percentage of Participants With A1C <7.0% (<53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Week 26

07

Results

Posted Oct 4, 2017
Limitations and caveats
After unblinding, analysis of retained plasma samples revealed unreported metformin use by \~17% of participants. Neither dose nor frequency of the protocol-prohibited metformin use is known. This potentially confounds glycemic analyses.

Participant flow

The trial was conducted in 13 countries, including 171 trial centers; 1709 participants were screened and 468 were randomized.

Participant flow — Overall Study
MilestoneErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Started158156154
Treated158155154
Completed145142143
Not completed131411
Withdrew: Adverse event100
Withdrew: Death344
Withdrew: Lost to follow-up210
Withdrew: Screen failure010
Withdrew: Participant moved002
Withdrew: Withdrawal by subject785

Outcome measures

PrimaryChange From Baseline in A1C at Week 26 - Excluding Rescue Approach

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percentage
Change From Baseline in A1C at Week 26 - Excluding Rescue Approach
PercentageErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in A1C at Week 26 - Excluding Rescue Approach-0.29 (-0.44 to -0.14)-0.41 (-0.56 to -0.27)-0.26 (-0.41 to -0.11)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = 0.807 (The cLDA model included fixed effects for treatment, time, eGFR stratum (\<45 or ≥45 mL/min/1.73m\^2), baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.03 · 95% CI -0.23 to 0.18
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = 0.155 (The cLDA model included fixed effects for treatment, time, eGFR stratum (\<45 or ≥45 mL/min/1.73m\^2), baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.15 · 95% CI -0.35 to 0.06
PrimaryPercentage of Participants Who Experienced an Adverse Event (AE)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 54 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Who Experienced an Adverse Event (AE)84.874.281.2
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in percentages vs. placebo: 3.6 · 95% CI -4.8 to 12.1Miettinen \& Nurminen Method
  • Ertugliflozin 15 mg vs Placebo · Difference in percentages vs. placebo: -7.0 · 95% CI -16.3 to 2.3Miettinen \& Nurminen Method
PrimaryPercentage of Participants Who Discontinued Study Treatment Due to an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Treatment Due to an AE
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Who Discontinued Study Treatment Due to an AE8.23.95.2
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Difference in percentages vs. placebo: 3.0 · 95% CI -2.7 to 9.0Miettinen \& Nurminen Method
  • Ertugliflozin 15 mg vs Placebo · Difference in percentages vs. placebo: -1.3 · 95% CI -6.5 to 3.7Miettinen \& Nurminen Method
SecondaryChange From Baseline in A1C at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percentage
Change From Baseline in A1C at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach
PercentageErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in A1C at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach-0.31 (-0.49 to -0.13)-0.37 (-0.56 to -0.18)-0.28 (-0.47 to -0.08)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = 0.828 (The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.03 · 95% CI -0.28 to 0.23
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = 0.496 (The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.09 · 95% CI -0.35 to 0.17
SecondaryChange From Baseline in Body Weight at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach
KilogramsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Body Weight at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach-1.31 (-1.86 to -0.76)-1.39 (-1.97 to -0.81)0.46 (-0.13 to 1.04)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 (The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable. P-value is nominal.) · Difference in the least squares means: -1.77 · 95% CI -2.57 to -0.96
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 (The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable. P-value is nominal.) · Difference in the least squares means: -1.84 · 95% CI -2.66 to -1.02
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

This change from baseline reflects the Week 26 sitting systolic blood pressure minus the Week 0 sitting systolic blood pressure. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach-2.33 (-4.98 to 0.33)-4.36 (-7.11 to -1.62)-0.90 (-3.73 to 1.92)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = 0.451 (The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -1.42 · 95% CI -5.13 to 2.29
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = 0.072 (The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -3.46 · 95% CI -7.24 to 0.31
SecondaryChange From Baseline in FPG at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach
mg/dLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in FPG at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach-11.76 (-21.07 to -2.45)-20.47 (-30.20 to -10.73)-4.95 (-15.03 to 5.13)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = 0.291 (The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -6.81 · 96% CI -19.47 to 5.85
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = 0.019 (The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable. P-value is nominal.) · Difference in the least squares means: -15.51 · 95% CI -28.50 to -2.53
SecondaryPercentage of Participants With A1C <7.0% (<53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C <7.0% (<53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants With A1C <7.0% (<53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach16.211.312.1
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Logistic regression model · p = 0.713 (Adjusted Odds Ratio based on a logistic regression model fitted with fixed effects for treatment, baseline treatment with insulin stratum (yes/no), and a covariate for baseline A1C.) · Adjusted odds ratio: 1.16 · 95% CI 0.53 to 2.56
  • Ertugliflozin 15 mg vs Placebo · Logistic regression model · p = 0.890 (Adjusted Odds Ratio based on a logistic regression model fitted with fixed effects for treatment, baseline treatment with insulin stratum (yes/no), and a covariate for baseline A1C.) · Adjusted odds ratio: 1.06 · 95% CI 0.44 to 2.55

Adverse events

Collected over Up to 54 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—24/154 (15.6%)68/154 (44.2%)
Ertugliflozin 5 mg—26/158 (16.5%)82/158 (51.9%)
Ertugliflozin 15 mg—30/155 (19.4%)62/155 (40%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventPlaceboErtugliflozin 5 mgErtugliflozin 15 mg
Angina pectorisCardiac disorders0/1540/1584/155
Acute myocardial infarctionCardiac disorders0/1542/1583/155
CellulitisInfections and infestations0/1540/1583/155
Coronary artery diseaseCardiac disorders2/1541/1581/155
Ischaemic strokeNervous system disorders2/1540/1580/155
Myocardial ischaemiaCardiac disorders0/1541/1582/155
Abdominal painGastrointestinal disorders0/1540/1582/155
Urinary tract infectionInfections and infestations0/1540/1582/155
Coronary artery stenosisCardiac disorders0/1542/1580/155
Sudden deathGeneral disorders1/1542/1581/155
Most frequent other events
Most frequent other events
EventPlaceboErtugliflozin 5 mgErtugliflozin 15 mg
HypoglycaemiaMetabolism and nutrition disorders45/15449/15832/155
Urinary tract infectionInfections and infestations15/1549/15812/155
Upper respiratory tract infectionInfections and infestations7/1549/15811/155
DiarrhoeaGastrointestinal disorders9/15410/1584/155
NasopharyngitisInfections and infestations7/1549/1586/155
DizzinessNervous system disorders1/1549/1582/155
CoughRespiratory, thoracic and mediastinal disorders2/1549/1583/155
BronchitisInfections and infestations6/1548/1582/155

Baseline characteristics

The Overall Number of Baseline Participants was the All-Participants-As-Treated population.

Age, Continuous
Age, Continuous(Years)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean66.7 ± 8.367.5 ± 8.567.5 ± 8.967.3 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Female748082236
Male847572231
Baseline Hemoglobin A1C (A1C)
Baseline Hemoglobin A1C (A1C)(Percentage)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean8.20 ± 1.028.17 ± 0.878.08 ± 0.898.15 ± 0.93
Baseline Weight
Baseline Weight(Kilograms)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean89.4 ± 22.585.8 ± 17.490.4 ± 18.988.5 ± 19.8
Baseline Fasting Plasma Glucose (FPG)
Baseline Fasting Plasma Glucose (FPG)(mg/dL)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean160.9 ± 56.4157.5 ± 47.8156.9 ± 56.4158.5 ± 53.6
Baseline Estimated glomerular filtration rate (eGFR)
Baseline Estimated glomerular filtration rate (eGFR)(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
≥30 to <45525354159
≥45 to <60106102100308
Stratification Factor: Insulin at randomization
Stratification Factor: Insulin at randomization(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
No696866203
Yes898788264
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, Jiang ZW, Golm G, Engel SS, Lauring B. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Ther. 2018 Feb;9(1):49-66. doi: 10.1007/s13300-017-0337-5. Epub 2017 Nov 20. PubMed 29159457 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗
  • Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9. PubMed 32648108 ↗
  • Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5. PubMed 32372382 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13. PubMed 32324082 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13. PubMed 32324065 ↗
  • Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3. PubMed 31797522 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Sep 2016, 33 months.

Results were first posted in Oct 2017, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 33 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2013
First posted
Nov 19, 2013
StartActual
Dec 2, 2013
Primary completionActual
Sep 28, 2016
CompletionActual
Sep 28, 2016
Results first posted
Oct 4, 2017
Last update
Sep 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01986855
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Nov 19, 2013
Start date
Dec 2, 2013
Primary completion
Sep 28, 2016
Completion
Sep 28, 2016
Results posted
Oct 4, 2017
Last update
Sep 10, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion